Depmap – A Cancer Dependency Map to systematically identify genetic and pharmacologic dependencies and the biomarkers that predict them.
Cancer Dependency Map
DepMap scientists are profiling hundreds of cancer cell line models for genomic information and sensitivity to genetic and small molecule perturbations. By triangulating information from these and other large-scale datasets, the hope is to define a landscape of genetic targets for therapeutic development, identify patients that who respond to these therapies, and develop a better understanding of the vulnerabilities of cancer.
The DepMap project at the Broad Institute is part of a strategic collaboration with theWellcome Sanger Institute (Hinxton, UK). By leveraging the expertise and infrastructure available at both organisations, we aim to more rapidly deliver a high-quality DepMap. We anticipate that this foundational dataset will catalyse a new wave of precision cancer medicines.